stockportfolio.pro
Stocks / IONS vs PEN
IONS vs PEN
Ionis Pharmaceuticals, Inc. and Penumbra, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ionis Pharmaceuticals, Inc. (IONS) | Penumbra, Inc. (PEN) | |
|---|---|---|
| Market cap | $12.2B | $12.6B |
| Revenue (latest FY) | $943.71M | $1.40B |
| Net income (latest FY) | $-381.39M | $177.69M |
| Revenue growth (5y CAGR) | 5.3% | 20.2% |
| Net margin | -40.4% | 12.7% |
| Return on equity | -78.0% | 12.4% |
| P/E ratio | — | 73.8 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 8 |
| Positive free cash flow | No | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open IONS — free Open PEN — freeFrequently asked questions
Which is bigger, IONS or PEN?
Penumbra, Inc. is larger by market capitalization — $12.6B versus $12.2B.
Which grows faster, IONS or PEN?
Over the last five fiscal years, Penumbra, Inc. grew revenue faster — 20.2%/yr versus 5.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.